A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma

BACKGROUND AND AIMS: Sorafenib is the first molecular targeted drug approved for the treatment of advanced hepatocellular carcinoma (HCC) and is a potent small molecule inhibitor of multiple kinases. Combination therapy with sorafenib and other cytotoxic agents for HCC may result in additive antican...

Descripción completa

Detalles Bibliográficos
Autores principales: Sho, Takuya, Nakanishi, Mitsuru, Morikawa, Kenichi, Ohara, Masatsugu, Kawagishi, Naoki, Izumi, Takaaki, Umemura, Machiko, Ito, Jun, Nakai, Masato, Suda, Goki, Ogawa, Koji, Chuma, Makoto, Meguro, Takashi, Nakamura, Michio, Nagasaka, Atsushi, Horimoto, Hiromasa, Yamamoto, Yoshiya, Sakamoto, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629128/
https://www.ncbi.nlm.nih.gov/pubmed/28573606
http://dx.doi.org/10.1007/s40268-017-0187-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629128/
https://www.ncbi.nlm.nih.gov/pubmed/28573606
http://dx.doi.org/10.1007/s40268-017-0187-7

Ejemplares similares